A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

Clinical trial NCT04993690 · RECRUITING

Trial details

NCT number: NCT04993690
Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

B-cell Lymphoma

Start date: 2021-07-06
Primary completion: 2026-12-31
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.